Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

5.73
+0.21503.90%
Volume:12.26K
Turnover:69.60K
Market Cap:49.30M
PE:-1.63
High:5.78
Open:5.57
Low:5.54
Close:5.51
52wk High:19.35
52wk Low:3.76
Shares:8.61M
Float Shares:8.61M
Volume Ratio:1.00
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5221
EPS(LYR):-3.0396
ROE:-48.89%
ROA:-29.87%
PB:0.99
PE(LYR):-1.88

Loading ...

FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer

Reuters
·
Jan 06

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

THOMSON REUTERS
·
Jan 06

Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction

Reuters
·
Dec 15, 2025

Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Dec 13, 2025

Why Are Shares Of Atossa Therapeutics Up Today?

Benzinga_recent_news
·
Dec 12, 2025

FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy

Reuters
·
Dec 11, 2025

Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods

Reuters
·
Dec 09, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

THOMSON REUTERS
·
Dec 09, 2025

Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study

Reuters
·
Dec 02, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Atossa Therapeutics Q3 net loss widens as operating costs rise

Reuters
·
Nov 12, 2025

Atossa Therapeutics Secures Israeli Patent for (Z)-Endoxifen, Strengthening Global IP Portfolio

Reuters
·
Nov 12, 2025

Atossa Therapeutics Q3 Pretax Profit USD -8.692 Million

THOMSON REUTERS
·
Nov 12, 2025

Atossa Therapeutics Q3 Operating Expenses USD 9.251 Million

THOMSON REUTERS
·
Nov 12, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

Atossa Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS

Reuters
·
Oct 21, 2025

Health Rounds: Scientists find way to make breast cancer drug work better for younger women

Reuters
·
Oct 17, 2025

Atossa Therapeutics appoints Mark Daniel as CFO

TIPRANKS
·
Oct 14, 2025